A recent analysis involving more than 100,000 patients with rheumatoid arthritis concluded that those receiving hydroxychloroquine (HCQ) had a lower risk of developing Alzheimer’s disease than those taking the immunosuppressant methotrexate. Nature‘s Molecular Psychiatry published the analysis. HCQ is a disease-modifying anti-rheumatic drug (DMARD) that can reduce pain and swelling associated with arthritis. It is also…
COVID drugs come in 3 flavors; it’s time for more diversity
Our industry’s response to COVID-19 defied the conventional wisdom that it takes years to deliver new drugs. Makers of monoclonal antibodies led the pack, most notably Regeneron (NSDQ:REGN), which manufactured the 8-g, two-antibody cocktail administered to then-President Donald Trump last fall. Eli Lilly (NYSE:LLY) and Vir Biotechnology (NSDQ:VIR) pulled off similar feats. Prior speed records…
Ivermectin not supported for mild COVID-19, study says
The antiparasitic drug ivermectin does not appear to be an efficacious COVID-19 treatment for mild COVID-19 cases, based on a randomized study recently published in JAMA. Ivermectin — which is widely used in veterinary medicine to get rid of worms and other parasites— emerged as a potential COVID-19 treatment, owing to its ability to inhibit…